Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 443

1.

Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.

Hou YX, Li CZ, Palaniyandi K, Magtibay PM, Homolya L, Sarkadi B, Chang XB.

Biochemistry. 2009 Sep 29;48(38):9122-31. doi: 10.1021/bi900675v.

2.

A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.

Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T.

Biochem J. 2003 Aug 1;373(Pt 3):767-74.

3.

Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.

Henriksen U, Gether U, Litman T.

J Cell Sci. 2005 Apr 1;118(Pt 7):1417-26. Epub 2005 Mar 15.

4.

Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers.

Bhatia A, Schäfer HJ, Hrycyna CA.

Biochemistry. 2005 Aug 16;44(32):10893-904.

PMID:
16086592
6.

The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.

Macalou S, Robey RW, Jabor Gozzi G, Shukla S, Grosjean I, Hegedus T, Ambudkar SV, Bates SE, Di Pietro A.

Cell Mol Life Sci. 2016 May;73(9):1927-37. doi: 10.1007/s00018-015-2118-5. Epub 2015 Dec 26.

PMID:
26708291
7.
8.

Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.

Ozvegy-Laczka C, Köblös G, Sarkadi B, Váradi A.

Biochim Biophys Acta. 2005 Feb 1;1668(1):53-63.

9.
10.
11.
13.

Functional characterization and ATP-induced dimerization of the isolated ABC-domain of the haemolysin B transporter.

Zaitseva J, Jenewein S, Wiedenmann A, Benabdelhak H, Holland IB, Schmitt L.

Biochemistry. 2005 Jul 19;44(28):9680-90.

PMID:
16008353
14.

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS.

Cancer Res. 2007 Nov 15;67(22):11012-20.

15.

Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.

Ozvegy-Laczka C, Várady G, Köblös G, Ujhelly O, Cervenak J, Schuetz JD, Sorrentino BP, Koomen GJ, Váradi A, Német K, Sarkadi B.

J Biol Chem. 2005 Feb 11;280(6):4219-27. Epub 2004 Nov 22.

16.

Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization.

Polgar O, Ozvegy-Laczka C, Robey RW, Morisaki K, Okada M, Tamaki A, Koblos G, Elkind NB, Ward Y, Dean M, Sarkadi B, Bates SE.

Biochemistry. 2006 Apr 25;45(16):5251-60.

17.

ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.

Nakagawa R, Hara Y, Arakawa H, Nishimura S, Komatani H.

Biochem Biophys Res Commun. 2002 Dec 13;299(4):669-75.

PMID:
12459192
18.

Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.

Henriksen U, Fog JU, Litman T, Gether U.

J Biol Chem. 2005 Nov 4;280(44):36926-34. Epub 2005 Aug 17.

19.

ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.

Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG.

Cancer Res. 2005 Sep 15;65(18):8414-22.

20.

Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD.

Cancer Res. 2003 Jul 15;63(14):4048-54.

Supplemental Content

Support Center